TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19361753

Group type: EXPERIMENTAL
Intervention: Fludarabine melphalan + alemtuzumab conditioning
Number of subjects: 154

Group type: COMPARATOR
Intervention: Fludarabine melphalan conditioning (control)
Number of subjects: 154
Study: 17710782

Group type: EXPERIMENTAL
Intervention: Seropositive patients for C. pneumoniae
Number of subjects: 271

Group type: COMPARATOR
Intervention: Seronegative patients for C. pneumoniae
Number of subjects: 271
Study: 15383080

Group type: EXPERIMENTAL
Intervention: Ventilation/perfusion tomography (V/P(SPET))
Number of subjects: 53

Group type: COMPARATOR
Intervention: Planar lung ventilation/perfusion scintigraphy (V/P(PLANAR))
Number of subjects: 53
Study: 11431615

Group type: EXPERIMENTAL
Intervention: Homeopathic treatment with APIS MELLIFICA 9 CH and BRYONIA 9 CH
Number of subjects: 71

Group type: COMPARATOR
Intervention: Basic treatment comprising naproxen and fluid restriction
Number of subjects: 71
Study: 9494026

Group type: EXPERIMENTAL
Intervention: Packed cells without buffy coat (PC)
Number of subjects: 914

Group type: EXPERIMENTAL
Intervention: Fresh-filtered units (FF)
Number of subjects: 914

Group type: EXPERIMENTAL
Intervention: Stored-filtered units (SF)
Number of subjects: 914
Study: 8039540

Group type: EXPERIMENTAL
Intervention: 300 ml grapefruit juice taken simultaneously with 10 mg coumarin
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 300 ml grapefruit juice taken 30 min prior to 10 mg coumarin
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: coadministration of grapefruit juice with 10 mg coumarin
Number of subjects: 13
Study: 2646997

Group type: EXPERIMENTAL
Intervention: Epinephrine (0.5 mg)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Methoxamine (5 mg)
Number of subjects: 102
Study: 31944318

Group type: EXPERIMENTAL
Intervention: Palliative consultation
Number of subjects: 188

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 188
Study: 30816640

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg subcutaneously Q6M
Number of subjects: 795

Group type: COMPARATOR
Intervention: Risedronate 5 mg orally QD
Number of subjects: 795
Study: 28056435

Group type: EXPERIMENTAL
Intervention: Repeat-PGE2
Number of subjects: 245

Group type: COMPARATOR
Intervention: Amniotomy
Number of subjects: 245
Study: 24830710

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 1144

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 1144
Study: 23960051

Group type: EXPERIMENTAL
Intervention: Pabrinex supplemented with magnesium sulphate (n=18)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Pabrinex only (n=18)
Number of subjects: 36
Study: 21818722

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: rTMS (non-invasive low-frequency repetitive transcranial magnetic stimulation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (TMS device as placebo)
Number of subjects: 0
Study: 18091268

Group type: EXPERIMENTAL
Intervention: Coiling treatment
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Clipping treatment
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Impact of anosmia
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Improvement of symptoms
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Risk factors for anosmia
Number of subjects: 315
Study: 16127299

Group type: EXPERIMENTAL
Intervention: 500 mg phytosterols
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 300 mg phytosterols
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 200 mg phytosterols
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 11908511

Group type: EXPERIMENTAL
Intervention: Short-acting beta2-agonist (salbutamol)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Long-acting beta2-agonist (formoterol)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 10452629

Group type: EXPERIMENTAL
Intervention: Fluconazole 200 mg per week
Number of subjects: 323

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323
Study: 7606068

Group type: EXPERIMENTAL
Intervention: 3-L WBI at 2 L/h
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 8-L WBI at 2 L/h
Number of subjects: 9
Study: 2218650

Group type: EXPERIMENTAL
Intervention: Diet supplemented with 20.4 g of psyllium daily
Number of subjects: 59

Group type: COMPARATOR
Intervention: Diet only
Number of subjects: 59
Study: 319322

Group type: EXPERIMENTAL
Intervention: Methandrostenolone
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 29493059

Group type: EXPERIMENTAL
Intervention: Ultrafiltration (UF)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Pharmacological therapy
Number of subjects: 188
Study: 27288389

Group type: EXPERIMENTAL
Intervention: Competing interest statements in Clinical Reviews
Number of subjects: 2040
Study: 24976452

Group type: EXPERIMENTAL
Intervention: Withholding breastfeeding before and after vaccination
Number of subjects: 400

Group type: COMPARATOR
Intervention: Breastfeeding half an hour before and after vaccination
Number of subjects: 400
Study: 22127230

Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (flavored water)
Number of subjects: 7
Study: 21114174

Group type: EXPERIMENTAL
Intervention: Low level nitrogen laser therapy along with antitubercular treatment (ATT)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Chemotherapy (ATT only)
Number of subjects: 104
Study: 19281914

Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg pretreatment >12 hours before coronary stenting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prasugrel (60 mg loading dose, 10 mg/d maintenance dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clopidogrel 300 mg loading dose administered at least 15 hours before elective PCI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg pretreatment before diagnostic catheterization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clopidogrel 300 mg pretreatment before elective PCI
Number of subjects: 0
Study: 15954913

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily
Number of subjects: 687

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: Higher baseline CRP level
Number of subjects: 687

Group type: EXPERIMENTAL
Intervention: Tertile of sTNFrii
Number of subjects: 687
Study: 12585987

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antioxidant vitamin supplements (vitamins E and C)
Number of subjects: 0
Study: 10636510

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 or 150 mg/day)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (0.625 mg/day)
Number of subjects: 415

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Raloxifene (combined groups)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Estrogen
Number of subjects: 415
Study: 8592021

Group type: EXPERIMENTAL
Intervention: Hormone therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Educational materials and counseling
Number of subjects: 0
Study: 1549991

Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 84
Study: 3923180

Group type: EXPERIMENTAL
Intervention: Penicillin V
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Cefadroxil
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study: 30132393

Group type: EXPERIMENTAL
Intervention: Line graph format indicating 'better'
Number of subjects: 1017

Group type: EXPERIMENTAL
Intervention: Line graph format indicating 'more' (better for function, worse for symptoms)
Number of subjects: 1017

Group type: EXPERIMENTAL
Intervention: Line graph format indicating 'normed' to a population average
Number of subjects: 1017
Study: 27586249

Group type: EXPERIMENTAL
Intervention: linagliptin 5 mg for 4 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: placebo for 4 weeks
Number of subjects: 62
Study: 25187002

Group type: EXPERIMENTAL
Intervention: Left vagus nerve stimulation (VNS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Right vagus nerve stimulation (VNS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined population (both left and right VNS)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Right-side ART
Number of subjects: 60
Study: 22916819

Group type: EXPERIMENTAL
Intervention: Low-GI meal (lentil-based, GI about 42)
Number of subjects: 14

Group type: COMPARATOR
Intervention: High-GI meal (potato-based, GI about 78)
Number of subjects: 14
Study: 19858315

Group type: EXPERIMENTAL
Intervention: Transdermal E(2)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: GHRH stimulation
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: GHRP-2 stimulation
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 17922458

Group type: EXPERIMENTAL
Intervention: HAMA‐IgM ELISA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HAMA‐IgG ELISA
Number of subjects: 0
Study: 15801940

Group type: EXPERIMENTAL
Intervention: Ultramolecular homeopathic medicines in C-30 potency administered twice weekly for 12 weeks
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study: 12145064

Group type: COMPARATOR
Intervention: Placebo IV
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 25 microg/kg of midazolam IV
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 50 microg/kg of midazolam IV
Number of subjects: 72
Study: 10610626

Group type: EXPERIMENTAL
Intervention: Communication skills training program 'Thriving in a Busy Practice: Physician‐Patient Communication' consisting of two 4‐hour interactive workshops
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (no communication skills training)
Number of subjects: 69
Study: 8916472

Group type: EXPERIMENTAL
Intervention: Estradiol vaginal ring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: First and second estradiol vaginal ring
Number of subjects: 0
Study: 1379969

Group type: EXPERIMENTAL
Intervention: Orgaran (loading dose of 1,000 anti‐Xa units intravenously followed by 750 anti‐Xa units subcutaneously 12‐hourly)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Orgaran (750 anti‐factor Xa units subcutaneously 12‐hourly)
Number of subjects: 162

Group type: COMPARATOR
Intervention: Unfractionated heparin (5,000 units subcutaneously 12‐hourly)
Number of subjects: 162
Study: 6387208

Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31701607

Group type: EXPERIMENTAL
Intervention: Deficient sleep (4 hours per night)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Normal sleep (7-8 hours per night)
Number of subjects: 22
Study: 30646102

Group type: EXPERIMENTAL
Intervention: Training sample (2113 patients)
Number of subjects: 4227

Group type: EXPERIMENTAL
Intervention: Test sample (1057 patients)
Number of subjects: 4227

Group type: EXPERIMENTAL
Intervention: Validation sample (1057 patients)
Number of subjects: 4227

Group type: EXPERIMENTAL
Intervention: Risk model (C statistics)
Number of subjects: 4227

Group type: EXPERIMENTAL
Intervention: Latent class model (C statistic)
Number of subjects: 4227

Group type: EXPERIMENTAL
Intervention: Risk stratification
Number of subjects: 4227
Study: 26554661

Group type: EXPERIMENTAL
Intervention: Testosterone therapy for 1 year
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study: 23443441

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg once daily (n=213)
Number of subjects: 422

Group type: COMPARATOR
Intervention: Placebo (n=209)
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 422
Study: 21595575

Group type: EXPERIMENTAL
Intervention: Da-Cheng-Qi decoction (DCQD) administered for 7 days
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Da-Cheng-Qi decoction (DCQD) in SAP rat models
Number of subjects: 70
Study: 19556579

Group type: EXPERIMENTAL
Intervention: Free soap and handwashing promotion for 9 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Former intervention households
Number of subjects: 0
Study: 16705588

Group type: COMPARATOR
Intervention: Protease inhibitor-based treatment
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: EFV-based treatment
Number of subjects: 355

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 355
Study: 15271009

Group type: EXPERIMENTAL
Intervention: Patient-activated cardioversion with sedation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Automatic night cardioversion with sedation
Number of subjects: 15

Group type: COMPARATOR
Intervention: Automatic night cardioversion without sedation
Number of subjects: 15
Study: 11747870

Group type: EXPERIMENTAL
Intervention: Oral contraceptive preparations (three different marketed OC preparations)
Number of subjects: 818

Group type: COMPARATOR
Intervention: Previous OC users (switchers)
Number of subjects: 818

Group type: COMPARATOR
Intervention: Non-hormonal birth control methods (starters)
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: Oral contraceptive preparations (during treatment)
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: Laboratory screening for APC-resistance using Coatest APC, ProC Global, or ProC APC-FV-Leiden
Number of subjects: 818
Study: 9242856

Group type: EXPERIMENTAL
Intervention: Added-purpose occupation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Rote exercise condition
Number of subjects: 20
Study: 8295815

Group type: EXPERIMENTAL
Intervention: Clarithromycin suspension, 7.5 mg/kg twice daily
Number of subjects: 506

Group type: COMPARATOR
Intervention: Penicillin VK suspension, 13.3 mg/kg three times per day
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 506

Group type: COMPARATOR
Intervention: Penicillin
Number of subjects: 506
Study: 2830588

Group type: EXPERIMENTAL
Intervention: CMV immunoglobulin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no CMV immunoglobulin)
Number of subjects: 60
Study: 30570356

Group type: EXPERIMENTAL
Intervention: Remote magnetic navigation (RMN)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Manually guided catheter ablation (MAN)
Number of subjects: 70
Study: 27809637

Group type: EXPERIMENTAL
Intervention: BBT (anthocyanin-rich black soybean testa extracts), 2.5 g/d
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo (starch), 2.5 g/d
Number of subjects: 63
Study: 24902398

Group type: EXPERIMENTAL
Intervention: 8% arginine calcium carbonate (CaCO3) desensitizing paste
Number of subjects: 303

Group type: COMPARATOR
Intervention: 5% potassium nitrate (KNO3) toothpaste
Number of subjects: 303
Study: 22696266

Group type: EXPERIMENTAL
Intervention: KN38-7271 high-dose (1000 μg)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: KN38-7271 low-dose (500 μg)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: KN38-7271 (both doses)
Number of subjects: 97
Study: 20683847

Group type: EXPERIMENTAL
Intervention: PEG‐IFN alfa‐2b (1.5 μg/kg/week) plus RBV (800‐1,400 mg/day) for 48 weeks
Number of subjects: 1428

Group type: EXPERIMENTAL
Intervention: PEG‐IFN alfa‐2b (1.5 μg/kg/week) plus RBV (800‐1,400 mg/day) for 72 weeks
Number of subjects: 1428

Group type: COMPARATOR
Intervention: PEG‐IFN alfa‐2b plus RBV for 72 weeks
Number of subjects: 1428

Group type: COMPARATOR
Intervention: PEG‐IFN alfa‐2b plus RBV for 48 weeks
Number of subjects: 1428
Study: 18615370

Group type: COMPARATOR
Intervention: Transvenous LV-lead placement
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Epicardial LV-lead placement
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 80
Study: 19578239

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy
Number of subjects: 2857
Study: 16393219

Group type: EXPERIMENTAL
Intervention: Senna (24 tablets of 12 mg, divided into two doses at 1 p.m. and 9 p.m.)
Number of subjects: 283

Group type: COMPARATOR
Intervention: PEG-ES (4-L standard solution)
Number of subjects: 283
Study: 12482664

Group type: EXPERIMENTAL
Intervention: BBG2Na vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9773734

Group type: EXPERIMENTAL
Intervention: Domperidone 20 mg q.i.d. (n=105)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Placebo (n=103)
Number of subjects: 269
Study: 7921758

Group type: EXPERIMENTAL
Intervention: Daily oral low-dose cyclophosphamide (CY) after failure of a monthly pulse regimen
Number of subjects: 4

Group type: COMPARATOR
Intervention: Monthly pulse regimen of cyclophosphamide (CY)
Number of subjects: 4
Study: 3078575

Group type: EXPERIMENTAL
Intervention: Oral whole cell anti-ETEC vaccine (approx. 3 X 10(10) vaccine cells)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 11483077

Group type: EXPERIMENTAL
Intervention: Cryotherapy (treated)
Number of subjects: 255

Group type: COMPARATOR
Intervention: No cryotherapy (control)
Number of subjects: 255
Study: 31515880

Group type: EXPERIMENTAL
Intervention: Shared Decision Making (SDM) during the general consent process; 90 physicians (88%) engaged in SDM
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Discussion of end of life issues during consent; 63 physicians (62%)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Use of existing SDM tools; 44 physicians (43%) used an SDM tool, with Colorado SDM tool being the most common (39; 89%)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Awareness of sex-based differences in perceptions related to ICD implantation; 64 physicians (63%) unaware
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Awareness of race-based differences in perceptions related to ICD implantation; 63 physicians (62%) unaware
Number of subjects: 124
Study: 30343311

Group type: EXPERIMENTAL
Intervention: PCOS patients
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal-weight PCOS patients
Number of subjects: 80

Group type: COMPARATOR
Intervention: Overweight PCOS patients
Number of subjects: 80

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 80
Study: 27251407

Group type: EXPERIMENTAL
Intervention: Vigorous running
Number of subjects: 22

Group type: COMPARATOR
Intervention: Vigorous cycling
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (30 min post-exercise)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cartilage thickness
Number of subjects: 22
Study: 25549482

Group type: EXPERIMENTAL
Intervention: Local anesthetic dose adjusted based on intra-abdominal pressure (IAP)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Local anesthetic dose not adjusted based on IAP
Number of subjects: 170
Study: 23017069

Group type: EXPERIMENTAL
Intervention: 10-week balance training regime (1-hour training, three times per week)
Number of subjects: 80
Study: 20420960

Group type: EXPERIMENTAL
Intervention: Group education programme once a week for 4 weeks, followed by a self‐executed home‐based exercise programme
Number of subjects: 50

Group type: COMPARATOR
Intervention: Brief course in short‐wave diathermy treatment
Number of subjects: 50
Study: 18092565

Group type: EXPERIMENTAL
Intervention: Surgical intervention for ASIA A patients with initial SBP < 90 mmHg
Number of subjects: 577

Group type: EXPERIMENTAL
Intervention: Surgical intervention for ASIA A patients with initial SBP >= 90 mmHg
Number of subjects: 577

Group type: COMPARATOR
Intervention: Comparison of time to surgical intervention based on SBP for ASIA A
Number of subjects: 577

Group type: COMPARATOR
Intervention: Neurogenic shock presence
Number of subjects: 577
Study: 16150205

Group type: EXPERIMENTAL
Intervention: Tripterygium glycosides tablet (TGT)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Radix Tripterygium hypoglaucum tablet (THT)
Number of subjects: 94
Study: 11819002

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Endotracheal Tube (ET)
Number of subjects: 60
Study: 10517046

Group type: EXPERIMENTAL
Intervention: Intrathecal recombinant, human brain‐derived neurotrophic factor (rhBDNF)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Revision of the catheter
Number of subjects: 1
Study: 7489345

Group type: EXPERIMENTAL
Intervention: 10 MU lymphoblastoid interferon
Number of subjects: 90

Group type: COMPARATOR
Intervention: 5 MU lymphoblastoid interferon
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both 10 MU and 5 MU lymphoblastoid interferon
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Sustained responders (10 MU and 5 MU)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Repeated liver biopsies (sustained responders)
Number of subjects: 90
Study: 2161436

Group type: EXPERIMENTAL
Intervention: Sunscreen applied to trunk
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Sunscreen applied to legs
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Sunscreen applied to entire body
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Sunscreen applied to head and neck
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Sunscreen applied to arms
Number of subjects: 27

Group type: COMPARATOR
Intervention: Whole body application of sunscreen
Number of subjects: 27
Study: 355183

Group type: EXPERIMENTAL
Intervention: EMD 21657 (3 x 300 mg for 6 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (3 x 1 dragee for 6 weeks)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: EMD 21657
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31935609

Group type: EXPERIMENTAL
Intervention: Residential density (RD) in tertiles
Number of subjects: 1568
Study: 31519391

Group type: EXPERIMENTAL
Intervention: Routine fluoroscopy (Group 1, n: 58)
Number of subjects: 125

Group type: COMPARATOR
Intervention: No fluoroscopy (Group 2, n: 67)
Number of subjects: 125
Study: 28299762

Group type: EXPERIMENTAL
Intervention: Complete Supine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Semi Supine
Number of subjects: 44
Study: 26393536

Group type: EXPERIMENTAL
Intervention: Full-frame 21.1-megapixel sensor
Number of subjects: 20

Group type: COMPARATOR
Intervention: Half-frame 18.0-megapixel sensor
Number of subjects: 20

Group type: COMPARATOR
Intervention: Compact 10.4-megapixel sensor
Number of subjects: 20
Study: 25167350

Group type: EXPERIMENTAL
Intervention: Lyophilized bone allograft mixed with platelet growth factors (experimental group)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Lyophilized bone allograft alone (control group)
Number of subjects: 16